There are 2789 resources available
693P - Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy
Presenter: Maryam Soleimani
Session: ePoster Display
694P - Methylthioadenosine phosphorylase (MTAP) deletion is more common in sarcomatoid (srcRCC) than in clear cell renal cell carcinoma (ccRCC)
Presenter: Andrea Necchi
Session: ePoster Display
695P - Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
Presenter: Marzia Del Re
Session: ePoster Display
719TiP - SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy
Presenter: Michiel van der Heijden
Session: ePoster Display
720TiP - Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Presenter: Rohit Jain
Session: ePoster Display
727P - Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
Presenter: Alexandra Leary
Session: ePoster Display
728P - A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer
Presenter: Erika Hamilton
Session: ePoster Display
729P - Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC)
Presenter: Judith Kroep
Session: ePoster Display
730P - Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study
Presenter: Huaying Wang
Session: ePoster Display
731P - Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study
Presenter: Robert Morgan
Session: ePoster Display